Suggested remit: To appraise the clinical and cost effectiveness of capmatinib within its marketing authorisation for treating locally advanced or metastatic non-small-cell lung cancer (NSCLC) with mesenchymal–epithelial transition (MET) exon 14 (METex14) skipping mutations.
Status In progress
Process STA 2018
ID number 1387

Provisional Schedule

Expected publication 14 December 2022

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
08 September 2021 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during early Feb- 2022 when we will write to consultees and commentators about how they can get involved. These timelines are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive submission.
09 July 2021 - 06 August 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
15 December 2017 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance